Displaying 134 (all) recruiting clinical trials.
-
RevMed RMC-6236-001: A Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Mutations in KRAS at Position G12.
This study is testing a new medicine, RMC-6236, for patients with certain advanced cancers that have specific changes in a gene called RAS. RMC-6236 aims ...
-
A Phase 1b Study to Evaluate the Safety Tolerability and Preliminary Efficacy of ATP150/ATP152 VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
This study is designed for patients with resected KRAS G12D/G12V mutated pancreatic cancer.This is an open-label, phase 1b study comprising of two parts ...
-
A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors. This is a study for the first time testing of a new medicine called ...
-
A Phase 2 Randomized Study to Evaluate the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inh
This research study aims to find out if two medicines, livmoniplimab (a special drug used to boost the body's ability to fight liver cancer ...
-
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other se
The purpose of the trial is to study a drug called BI 907828 for the treatment of certain types of advanced or spreading tumors. These ...
-
A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 AN ANTI-CD22 X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY IN COMBINATION WITH ODRONEXTAMAB AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY IN PATIENTS WITH AGGRESSIVE
The goal of this study is to investigate how safe and effective the combining of two different antibodies, REGN5837 and odronextamab (REGN1979), is in patients ...
-
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
This study will focus on improving chemotherapy response rates in both primary and metastatic rectal and colorectal cancer. In this study, patients will be divided ...
-
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB WITH AND WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
This study is testing if a new treatment works for patients with hepatocellular carcinoma (HCC) that's either very advanced or has spread to other ...
-
A single arm phase II study of ADjuvant Endocrine therapy subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive HER2-positive breast cancer (ADEPT)
You can participate in this study if you are diagnosed with stage I, hormone receptor-positive (HR+) and human epidermal growth factor receptor-2.positive (HER2+) breast ...
-
A Phase 3 Randomized Double-blind Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
This research study is for people who are 12 years of age or older and weigh at least 40 kg, and who have had surgery ...